N
Nathan Hambly
Researcher at McMaster University
Publications - 64
Citations - 672
Nathan Hambly is an academic researcher from McMaster University. The author has contributed to research in topics: Medicine & Interstitial lung disease. The author has an hindex of 10, co-authored 39 publications receiving 376 citations. Previous affiliations of Nathan Hambly include St. Joseph's Healthcare Hamilton & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
Monoclonal antibodies for the treatment of refractory asthma.
Nathan Hambly,Parameswaran Nair +1 more
TL;DR: A small proportion of patients with asthma have severe disease characterized by persistent airflow obstruction, airway hyperresponsiveness and eosinophilic airway inflammation as mentioned in this paper, and the clinical efficacy of inhibiting T helper 2-cytokine-mediated inflammatory respo
Journal ArticleDOI
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Kerri A. Johannson,Irina Strâmbu,Claudia Ravaglia,Jan C. Grutters,Claudia Valenzuela,Nesrin Mogulkoc,Fabrizio Luppi,Luca Richeldi,Athol U. Wells,Carlo Vancheri,Michael Kreuter,Carlo Albera,Katerina M. Antoniou,Goksel Altinisik,Elisabeth Bendstrup,Benjamin Bondue,Raphael Borie,Kevin K. Brown,Philippe Camus,Diego Castillo,Harold R. Collard,Vincent Cottin,Nunzio Crimi,Giovanni Ferrara,Aryeh Fischer,Jack Gauldie,Thomas Geiser,Andreas Guenther,Nathan Hambly,David M. Hansell,Sergio Harari,Mark Jones,Michael P. Keane,Brett Ley,Toby M. Maher,Maria Molina-Molina,Stefano Palmucci,Venerino Poletti,Antje Prasse,Paola Rottoli,Paolo Spagnolo,Martina Sterclova,Sebastiano Alfio Torrisi,Eliza Tsitoura,Martina Vasakova,Simon L.F. Walsh,Marlies S. Wijsenbeek,Wim Wuyts +47 more
TL;DR: The literature addressing the association between GER and IPF is summarized, the process through which the guideline recommendation was achieved is shed, and future research priorities that could clarify this issue are identified.
Journal ArticleDOI
Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.
Alyson W. Wong,Alyson W. Wong,Lee Fidler,Veronica Marcoux,Kerri A. Johannson,Deborah Assayag,Jolene H. Fisher,Nathan Hambly,Martin Kolb,Julie Morisset,Shane Shapera,Christopher J. Ryerson,Christopher J. Ryerson +12 more
TL;DR: The goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.
Journal ArticleDOI
Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers.
TL;DR: Although the search for candidate biomarkers remains in its infancy, attractive targets such as MUC5B and MPP7 have already been validated in large cohorts and have demonstrated their potential to improve clinical predictors beyond that of routine clinical practices.
Journal ArticleDOI
Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
Jolene H. Fisher,Jolene H. Fisher,Martin Kolb,Mohmmed Algamdi,Julie Morisset,Kerri A. Johannson,Shane Shapera,Pearce G. Wilcox,T.M. To,Mohsen Sadatsafavi,Hélène Manganas,Nasreen Khalil,Nathan Hambly,Andrew J. Halayko,Andrea S. Gershon,Charlene D. Fell,Gerard Cox,Christopher J. Ryerson +17 more
TL;DR: CTD-ILD, IPF, and unclassifiable ILD made up 80% of ILD diagnoses at ILD referral centers in Canada, while idiopathic NSIP was rare when adhering to recommended diagnostic criteria.